Role of pathologists in nomogram development: reply.

Pathology

Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia. Electronic address:

Published: December 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2023.09.001DOI Listing

Publication Analysis

Top Keywords

role pathologists
4
pathologists nomogram
4
nomogram development
4
development reply
4
role
1
nomogram
1
development
1
reply
1

Similar Publications

Surgical pathologists who examine gastric biopsies must triage exuberant lymphoid infiltrates for hematopathology consultation, a task that should account for resource and time utilization. We assembled all cases of chronic gastritis sent by surgical pathologists to hematopathology due to concern for low-grade lymphoma over a 4-year interval. The cases were ultimately classified as reactive (n=37), atypical (n=9), or lymphoma (n=18).

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma (NHL) in humans, accounting for about 30-40% of NHL cases worldwide. Canine diffuse large B-cell lymphoma (cDLBCL) is the most common lymphoma subtype in dogs and demonstrates an aggressive biologic behaviour. For tissue biopsies, current confirmatory diagnostic approaches for enlarged lymph nodes rely on expert histopathological assessment, which is time-consuming and requires specialist expertise.

View Article and Find Full Text PDF

ERS/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease.

Ann Rheum Dis

September 2025

Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Department of Rheumatology, Oslo University Hospital, Oslo, Norway. Electronic address:

Background: Interstitial lung disease (ILD) is a frequent manifestation of connective tissue diseases (CTDs) and is associated with high morbidity and mortality. Clinical practice guidelines to standardise screening, diagnosis, treatment and follow-up for CTD-ILD are of high importance for optimised patient care.

Methods: A European Respiratory Society and European Alliance of Associations for Rheumatology task force committee, composed of pulmonologists, rheumatologists, pathologists, radiologists, methodologists and patient representatives, developed recommendations based on PICO (Patients, Intervention, Comparison, Outcomes) questions with grading of the evidence according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology and complementary narrative questions agreed on by both societies.

View Article and Find Full Text PDF

The evaluation and management of renal masses, predominantly of the clear cell renal cell carcinoma subtype, have been evolving over the past several years and demanding greater attention from nephrologists. Oncologic survival of localized tumors approaches 100%, where survival is more closely tied to underlying comorbidities including chronic kidney disease (CKD). Early diagnosis and thus increasing prevalence related to incidental discovery of renal masses allows greater emphasis on nephron-sparing procedures and for residual kidney function preservation.

View Article and Find Full Text PDF

Deep learning models applied to digital histology can predict gene expression signatures (GES) and offer a low-cost, rapidly available alternative to molecular testing at the time of diagnosis. We optimized transformer-based models to infer GES results and applied this approach to pre-treatment H&E-stained biopsies from 1,940 breast cancer patients treated with neoadjuvant chemotherapy in clinical trial and real-world cohorts. The most predictive histology-derived GES for pathologic complete response (pCR) in the I-SPY2 trial was validated in four external cohorts: CALGB 40601, CALGB 40603, a trial of durvalumab plus CT, and standard-of-care CT-treated patients from the University of Chicago.

View Article and Find Full Text PDF